A REAL-WORLD ANALYSIS OF TREATMENT PATTERNS FOR FIRST-LINE IMMUNOTHERAPIES AMONG DANISH PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND PD-L1 EXPRESSION $50%

被引：0
|
作者：
Clugston, D. M. [1 ]
Beck, C. [2 ]
Bjerregaard, B. K. [3 ]
Kristensen, E. S. [4 ]
机构：
[1] Roche Pharmaceut AS, Copenhagen, Denmark
[2] Roche Pharmaceut AS, Copenhagen 84, Denmark
[3] IQVIA Denmark, Copenhagen, Denmark
[4] IQVIA, Copenhagen, Denmark
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD53
引用
收藏
页码：S514 / S514
页数：1
相关论文
共 50 条
  • [1] Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis
    Ikezawa, Yasuyuki
    Morita, Ryo
    Mizugaki, Hidenori
    Tateishi, Kazunari
    Yokoo, Keiki
    Sumi, Toshiyuki
    Kikuchi, Hajime
    Kitamura, Yasuo
    Nakamura, Atsushi
    Kobayashi, Maki
    Aso, Mari
    Kimura, Nozomu
    Yoshiike, Fumiaki
    Megumi, Furuta
    Tanaka, Hisashi
    Sekikawa, Motoki
    Hachiya, Tsutomu
    Nakamura, Keiichi
    Hommura, Fumihiro
    Sukoh, Noriaki
    Ito, Kenichiro
    Kikuchi, Takashi
    Agatsuma, Toshihiko
    Yokouchi, Hiroshi
    CANCER MEDICINE, 2024, 13 (14):
  • [2] Real-World Data (RWD) Of First-Line Cemiplimab Single Agent for Advanced PD-L1 High Expression, Non-Small Cell Lung Cancer (NSCLC)
    Masini, S.
    Garrido, A.
    Alvarez, R.
    Antonanzas, M.
    Navarro, F.
    Traseira, C.
    Cabezon, L.
    Garcia, C.
    Falagan, S.
    Rocha, P.
    Mosquera, J.
    Azkarate, A.
    Garcia-Lorenzo, E.
    Martin-Soberon, M. C.
    Sequero, S.
    Sereno, M.
    Lage, Y.
    Peressini, M.
    Cortijo, S.
    Bote, H.
    Torres-Jimenez, J.
    Zurera, M.
    Paz-Ares, L.
    Zugazagoitia, J.
    Baena, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S405 - S405
  • [3] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
    Kuzminin, A.
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Naveira, M.
    Wainsztein, V.
    Lupinacci, L.
    Rizzi, M.
    Faura, M.
    Perfetti, A.
    Recondo, G., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
  • [4] Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)
    Yokouchi, H.
    Mizugaki, H.
    Ikezawa, Y.
    Morita, R.
    Tateishi, K.
    Yokoo, K.
    Sumi, T.
    Kikuchi, H.
    Nakamura, A.
    Kobayashi, M.
    Aso, M.
    Tsukita, Y.
    Yoshiike, F.
    Furuta, M.
    Tanaka, H.
    Sekikawa, M.
    Hachiya, T.
    Nakamura, K.
    Kitamura, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1574 - S1574
  • [5] Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Burke, Thomas
    CANCER RESEARCH, 2019, 79 (13)
  • [6] PD-L1 Testing Patterns and Treatment in Patients With Metastatic Non-Small Cell Lung Cancer in Israel - Analysis of Real-World Data
    Apter, L.
    Moser, S. Sharman
    Arunachalam, A.
    Burke, T.
    Shalev, V.
    Chodick, G.
    Siegelmann-Danieli, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S307 - S308
  • [7] Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States
    Veluswamy, Rajwanth
    Hirsch, Fred R.
    Taioli, Emanuela
    Wisnivesky, Juan
    Strauss, Ross
    Harrough, Douglas
    Tang, Boxiong
    Barnes, Gisoo
    CANCER MEDICINE, 2022, 11 (22): : 4265 - 4272
  • [8] Real-World PD-L1 Testing Patterns for Patients with Advanced Non-Small Cell Lung Cancer in Greece
    Kokkotou, E.
    Charpidou, A.
    Papaspiliou, A.
    Stournara, L.
    Grammatikou, V.
    Ejzykowicz, F.
    Syrigos, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S660 - S660
  • [9] PD-L1 Expression, EGFR and KRAS Mutations in First-Line Therapy (1L) for Non-Small Cell Lung Cancer (NSCLC) Patients
    Cronin-Fenton, D.
    Dalvi, T.
    Hedgeman, E.
    Norgaard, M.
    Petersen, L.
    Hansen, H.
    Fryzek, J.
    Lawrence, D.
    Walker, J.
    Mellemgaard, A.
    Rasmussen, T.
    Shire, N.
    Rigas, J.
    Potter, D.
    Hamilton-Dutoit, S.
    Sorensen, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2084 - S2085
  • [10] Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: a Real-World Australian Perspective
    Prabhakaran, S.
    Russell, P. A.
    Farrall, A. L.
    Asadi, K.
    Barrett, W.
    Cooper, C.
    Cooper, W.
    Duhig, E. E.
    Egan, M.
    Fox, S.
    Godbolt, D.
    Gupta, S.
    Cotton, S.
    Leslie, C.
    Leong, T.
    Moffat, D.
    Qiu, M.
    Sivasubramaniam, V.
    Snell, C.
    Skerman, J.
    Walsh, M.
    Whale, K.
    Klebe, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S479 - S479
12345